OncoCyte announces peer-reviewed publication of DetermaIO study

Oncocyte announces the peer-reviewed publication of the results of a study applying DetermaIO to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer. The results were published in Clinical Cancer Research and "showed the utility of DetermaIO in potentially identifying more responders to ICI therapy than current standard of care biomarkers," the company said in a statement. In the overall population of 122, DetermaIO positive patients achieved better outcomes in terms of progression-free survival from the addition of atezolizumab among mCRC patients than DetermaIO negative patients, regardless of MMR status, according to OncoCyte. A similar trend was observed in the pMMR population that does not currently qualify for ICI therapy in mCRC, it added.